SALIOGEN THERAPEUTICS

saliogen-therapeutics-logo

SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.

#SimilarOrganizations #People #Financial #Website #More

SALIOGEN THERAPEUTICS

Social Links:

Industry:
Biotechnology Genetics Life Science Therapeutics

Founded:
2020-01-01

Address:
Burlington, Massachusetts, United States

Country:
United States

Website Url:
http://www.saliogen.com

Total Employee:
11+

Status:
Active

Contact:
(650) 906-9468

Total Funding:
135 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins Global Site Tag


Similar Organizations

affinia-therapeutics-logo

Affinia Therapeutics

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.

cedilla-therapeutics-logo

Cedilla Therapeutics

Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.

enliven-therapeutics-logo

Enliven Therapeutics

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

parthenon-therapeutics-logo

Parthenon Therapeutics

Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.

ray-therapeutics-logo

Ray Therapeutics

Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases.

vigil-neuroscience-logo

Vigil Neuroscience

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.


Current Advisors List

sean-stalfort_image

Sean Stalfort Board Member @ SalioGen Therapeutics
Board_member

craig-gordon_image

Craig Gordon Board Member @ SalioGen Therapeutics
Board_member
2021-12-01

Current Employees Featured

not_available_image

Joseph Higgins
Joseph Higgins President & Chief Scientific Officer, Founder @ SalioGen Therapeutics
President & Chief Scientific Officer, Founder

sung-you_image

Sung You
Sung You Chief Business and Strategy Officer @ SalioGen Therapeutics
Chief Business and Strategy Officer
2021-07-01

ray-tabibiazar_image

Ray Tabibiazar
Ray Tabibiazar Chairman & CEO @ SalioGen Therapeutics
Chairman & CEO
2021-01-01

Founder


not_available_image

Joseph Higgins

Investors List

symbiosis-ii-llc_image

SymBiosis LLC

SymBiosis LLC investment in Series B - SalioGen Therapeutics

d1-capital-partners_image

D1 Capital Partners

D1 Capital Partners investment in Series B - SalioGen Therapeutics

fidelity-management-and-research-company_image

Fidelity Management and Research Company

Fidelity Management and Research Company investment in Series B - SalioGen Therapeutics

retinal-degeneration-fund_image

Retinal Degeneration Fund

Retinal Degeneration Fund investment in Series B - SalioGen Therapeutics

gordonmd-global-investments_image

GordonMD Global Investments

GordonMD Global Investments investment in Series B - SalioGen Therapeutics

the-cystic-fibrosis-foundation_image

Cystic Fibrosis Foundation

Cystic Fibrosis Foundation investment in Series B - SalioGen Therapeutics

t-rowe-price_image

T. Rowe Price

T. Rowe Price investment in Series B - SalioGen Therapeutics

epiq-capital-group_image

EPIQ Capital Group

EPIQ Capital Group investment in Series B - SalioGen Therapeutics

pbm-capital-group_image

PBM Capital Group

PBM Capital Group investment in Series A - SalioGen Therapeutics

Official Site Inspections

http://www.saliogen.com

  • Host name: 172.67.217.228
  • IP address: 172.67.217.228
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Saliogen.com lookup results from whois.cloudflare.com server:
  • Domain created: 17th-Oct-2019
  • Domain updated: 24th-Mar-2024
  • Domain expires: 17th-Oct-2027 2 Years, 115 Days left
  • Website age: 5 Years, 250 Days
  • Registrar Domain ID: 2444558790_DOMAIN_COM-VRSN
  • Registrar Url: http://www.cloudflare.com
  • Registrar WHOIS Server: whois.cloudflare.com
  • Registrar Abuse Contact Email: registrar-abuse@cloudflare.com
  • Registrar Abuse Contact Phone: +1.6503198930
  • Name server:
    • ALDO.NS.CLOUDFLARE.COM
    • MICHELLE.NS.CLOUDFLARE.COM

More informations about "SalioGen Therapeutics"

SalioGen Therapeutics - Crunchbase Company Profile …

SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding …See details»

SalioGen Therapeutics

The Company is no longer operating. Any questions may be submitted by email to: Saliogen@vlpc.com. Correspondence can also be sent to: SalioGen Therapeutics 124 …See details»

SalioGen Therapeutics - Overview, News & Similar companies

SalioGen Therapeutics Announces Selection of Development Candidate for ABCA4-mediated Stargardt Disease--SGT-1001 is the first development candidate using SalioGen's novel Gene …See details»

SalioGen Therapeutics | LinkedIn

SalioGen Therapeutics | 3,256 followers on LinkedIn. Accelerating the impact of genetic medicines for patients with Gene Coding™ technology | SalioGen Therapeutics is a …See details»

SalioGen Therapeutics - Craft

SalioGen Therapeutics is a company developing genetic medicine for patients with inherited disorders. It uses a genetic modification approach that works by adding a new genomic code …See details»

Saliogen Therapeutics - Products, Competitors, Financials, …

Saliogen Therapeutics is a biotechnology company focused on advancing genetic medicine through its innovative Gene Coding technology. The company's main offerings include non …See details»

SalioGen Therapeutics Strengthens its Leadership Team to

Jul 20, 2022 SalioGen is focused on developing therapies for more patients with inherited diseases that are beyond what is addressable with current technologies, initially focusing on …See details»

SalioGen Therapeutics 2025 Company Profile: …

SalioGen Therapeutics is headquartered in Foxboro, MA. What is the size of SalioGen Therapeutics? SalioGen Therapeutics has 75 total employees. What industry is SalioGen Therapeutics in? SalioGen Therapeutics’s primary …See details»

SalioGen Therapeutics hit by layoffs, as gene-editing …

Oct 13, 2024 SalioGen Therapeutics, a company that raised $135 million to develop a new gene-editing technology, has instituted widespread layoffs and is scaling back its ambitions.See details»

SalioGen Therapeutics Overview | SignalHire Company Profile

SalioGen Therapeutics is a biotechnology company on a mission to accelerate the impact of genetic medicine for patients using its novel Gene Coding™ technology. Gene Coding is a non …See details»

SalioGen Therapeutics - Contacts, Employees, Board Members

SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. ... Experience the new Crunchbase, powered by AI . …See details»

SalioGen Therapeutics Closes $115 Million Oversubscribed Series B ...

Jan 5, 2022 SalioGen is focused on developing therapies for more patients with inherited diseases that are beyond what is addressable with current technologies, initially focusing on …See details»

SalioGen Therapeutics Closes $115 Million Oversubscribed

Jan 5, 2022 SalioGen Therapeutics investors@saliogen.com. Media Contact: Amy Jobe, Ph.D. LifeSci Communications 315-879-8192 ajobe@lifescicomms.com. GordonMD Global …See details»

VCs plow $115M into next-gen genetic medicine startup SalioGen, …

Jan 5, 2022 SalioGen Therapeutics is moving quickly. Ten months after exiting stealth with $20 million in series A funds, the Massachusetts-based biotech has raised another $115 million to …See details»

SalioGen Therapeutics Announces Closing of $20 Million Series A ...

Introducing a mammal-derived genome engineering enzyme for next-generation gene and cell therapy Financing to fund SalioGen’s pipeline in genetic diseases, based on proprietary EDIT …See details»

SalioGen Therapeutics - Funding, Financials, Valuation & Investors

How much funding has this organization raised over time? Show . Announced Date . Transaction Name ... Money Raised . Lead Investors . Jan 5, 2022: Series B - SalioGen Therapeutics . 8: …See details»

How SalioGen’s attempt to turn ‘jumping genes’ into medicines …

May 2, 2025 SalioGen Therapeutics, led by Ray Tabibiazar, shut down after failing to perfect its bat-derived gene editing technology. Despite raising $115M, the company struggled with …See details»

SalioGen Therapeutics Strengthens Management with Key

Jul 28, 2021 SalioGen Therapeutics is advancing Gene Coding to develop durable, broadly applicable genetic medicines, initially using its Exact DNA Integration Technology (EDIT) …See details»

SalioGen Therapeutics Announces Closing of $20 Million

Mar 1, 2021 SalioGen is initially focused on providing durable, safe and affordable non-viral gene therapy to more patients with inherited diseases that are beyond what is addressable …See details»

SalioGen Therapeutics - Tech Stack, Apps, Patents & Trademarks

Organization. SalioGen Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 5. ...See details»

linkstock.net © 2022. All rights reserved